5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Titel:
5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Auteur:
Garon, E.B. Cho, B.C. Luft, A. Alatorre-Alexander, J. Geater, S.L. Trukhin, D. Kim, S-W. Ursol, G. Hussein, M. Lim, F.L. Yang, C-T. Araujo, L.H. Saito, H. Reinmuth, N. Medic, N. Mann, H. Shi, X. Peters, S. Mok, T.S.K. Johnson, M.